United Therapeutics Corporation $UTHR Shares Sold by First Turn Management LLC

First Turn Management LLC lessened its position in United Therapeutics Corporation (NASDAQ:UTHR) by 25.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 63,580 shares of the biotechnology company’s stock after selling 21,738 shares during the period. United Therapeutics makes up 3.5% of First Turn Management LLC’s portfolio, making the stock its 12th biggest position. First Turn Management LLC owned approximately 0.15% of United Therapeutics worth $30,979,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of UTHR. Entropy Technologies LP increased its stake in United Therapeutics by 61.7% during the 4th quarter. Entropy Technologies LP now owns 1,940 shares of the biotechnology company’s stock valued at $945,000 after buying an additional 740 shares during the period. Ariadne Wealth Management LP acquired a new position in United Therapeutics during the 4th quarter valued at about $217,000. Aptus Capital Advisors LLC acquired a new position in United Therapeutics during the 4th quarter valued at about $225,000. Kestra Advisory Services LLC increased its stake in United Therapeutics by 17.1% during the 4th quarter. Kestra Advisory Services LLC now owns 1,288 shares of the biotechnology company’s stock valued at $628,000 after buying an additional 188 shares during the period. Finally, CreativeOne Wealth LLC acquired a new position in United Therapeutics during the 4th quarter valued at about $1,530,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 634,984 shares of company stock worth $358,175,202. Company insiders own 8.60% of the company’s stock.

United Therapeutics Trading Up 0.1%

NASDAQ:UTHR opened at $545.96 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The company has a 50-day moving average of $566.75 and a 200-day moving average of $521.34. The firm has a market cap of $23.17 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the business posted $6.63 EPS. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the topic of several research analyst reports. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Raymond James Financial initiated coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Finally, Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.